Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab subcutaneous induction therapy in moderately to severely active Crohn's disease
CTR20221347Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of guselkumab in Crohn's disease, sponsored by Janssen Pharmaceutical. Started Sep 2022; status: active.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20221347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221347.